<?xml version="1.0" encoding="UTF-8"?>
<p>The 2 leading antiviral candidates are brincidofovir (Chimerix, Durham, NC) and favipiravir (Fujifilm, Toyama Chemical, Tokyo, Japan). Brincidofovir is currently in phase III clinical trials for use in human subjects against cytomegalovirus (CMV) and adenovirus after successful testing for safety in more than 1000 human subjects
 <xref rid="bib54" ref-type="bibr">
  <sup>54</sup>
 </xref> and has received US Food and Drug Administration Fast Track Designation for treatment of CMV, adenovirus, and smallpox.
 <xref rid="bib55" ref-type="bibr">
  <sup>55</sup>
 </xref> On October 6, 2014, Chimerix received a US Food and Drug Administration authorization for emergency investigational new drug applications of brincidofovir for the treatment of EVD, but of late, the company has decided to focus their efforts on its use in CMV and adenovirus infections.
</p>
